The Oncologist

09/25/2025

Huge thanks to our Deputy Editors and for proudly representing The Oncologist at earlier this month. We’re grateful for your leadership!

09/25/2025

⬆️ in (under 50) demands specialized programs. Study with 7 🇺🇸🇨🇦leaders propose a 10-step blueprint for development: Program manager for monitoring. Addresses unique needs

AbstractBackground. The incidence of individuals diagnosed with colorectal cancer under the age of 50, often referred to as early-onset colorectal cancer (

09/23/2025

In this meta-analysis of 64 studies, was confirmed to increase the risk of hypertension (all-grade=50%, grade ≥3=14%) & proteinuria (all-grade=32%, grade ≥3=6%), esp. with high doses (≥20mg). Close monitoring is required.

AbstractBackground. Published data regarding the overall risks and incidence of hypertension and proteinuria associated with lenvatinib remain unclear.Meth

09/22/2025

This review summarizes the advantages & limitations of various detection strategies in oncology: 🧬PCR-based tests: Sensitive, cost-effective, but limited gene scope 🧬NGS: Broad genotyping & detects actionable mutations

Abstract. Complete oveview of ctDNA detection methods.The analysis of circulating tumor DNA (ctDNA) has emerged as a major minimally invasive biomarker in

09/19/2025

In patients with (1–3 LN mets), selective LN dissection + adjuvant immunotherapy (IO) achieved a 2-yr RRFS of 65.7%, with low morbidity. This supports avoiding full LN dissection when feasible, esp. when 1L neoadjuvant IO is not suitable.

AbstractBackground. Therapeutic lymph node dissection has shown no clear benefits in terms of overall survival. However, appropriate regional control has r

09/18/2025

Across 9 studies involving patients with cT4 , laparoscopic colectomy (LC) was linked to a higher risk of peritoneal recurrence vs open colectomy (OR 1.61; HR 1.24). Hence, LC should be approached with caution in this high-risk patient subset.

AbstractBackground. Locally advanced (T4) colon cancer is a significant risk factor for peritoneal metastasis (PM). Although laparoscopic colectomy (LC) is

09/17/2025

+ gemcitabine/cisplatin significantly improved OS & PFS vs chemo alone across 10 studies (n=2877) in this meta-analysis on 1L therapy in advanced biliary tract cancer.
https://doi.org/10.1093/oncolo/oyaf224

09/15/2025

In this systematic review of 22 studies involving older adults with cancer, was generally stable long-term, but declined during treatment & in the last year of life. Comorbidities, older age, & mobility issues predicted decline.
https://doi.org/10.1093/oncolo/oyaf223

09/11/2025

In early-stage , chemo + ICI achieved 50% pCR (vs 35.9% with chemo alone), albeit lower than trial rates. Less pronounced real-world benefit needs further validation in a larger cohort.

AbstractBackground. Our objective is to compare the response rate between two matched cohorts of early-stage TNBC (chemotherapy: CT + immune checkpoint inh

09/10/2025

In 6 🇹🇷 centers, pts treated with 177Lu-PSMA-617, prior (vs ) linked to ⬆️ PFS (7.6 vs 5.3 mo, P=0.068), ⬆️ OS (12.8 vs 6.9 mo, P=0.021) Sequencing is 🔑

AbstractBackground. Prostate-specific membrane antigen (PSMA) is a key target in metastatic castration resistance prostate cancer (mCRPC). Enzalutamide, an

09/09/2025

2025 International Urology Cancer Summit Abstracts
https://academic.oup.com/oncolo/issue/30/Supplement_1

09/08/2025

Low-dose methadone with ongoing opioid treatment shows potential efficacy in the management of refractory cancer pain with acceptable mild/moderate adverse events, making it a promising option.
https://doi.org/10.1093/oncolo/oyaf215